Glenn D. Steele Jr. named chair of City of Hope board of directors

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Glenn D. Steele Jr. was elected board chair of City of Hope, effective June 1.

Steele joined the City of Hope Board of Directors in January 2016. Prior to becoming chair, he was chair of the Executive Compensation and Governance Committee from 2018-2020.

Selwyn Isakow, founder and chief executive officer of The Oxford Investment Group, is the immediate past chair.

His investigations have focused on the cell biology of gastrointestinal cancer and pre-cancer and, most recently, on innovations in health care delivery and financing.

Steele serves as chairman of GSteele Health Solutions, an independently-operated venture launched to help health care organizations create value and improve quality. He is the former chairman of xG Health Solutions and former president and chief executive officer of Geisinger Health System, an integrated health services organization recognized for its innovative use of the electronic health record and the development and implementation of care models.

Steele is past chairman of the American Board of Surgery, and serves on for-profit and not-for-profit boards and national committees, including vice chair of Health Transformation Alliance, Bucknell University Board of Trustees as an emeritus trustee, Stanford Board of Fellows, Peterson Center on Healthcare Advisory Board, and serves as an adviser on the private equity firms of General Atlantic and LRVHealth.

Steele is a member of the National Academy of Medicine and has served as the dean of the Biological Sciences Division and the Pritzker School of Medicine and vice president for medical affairs at University of Chicago, as well as the Richard T. Crane Professor in the Department of Surgery. Prior to that, he was the William V. McDermott Professor of Surgery at Harvard Medical School.

Table of Contents

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login